Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
NCT ID: NCT04626089
Last Updated: 2021-04-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE2
Study Classification
INTERVENTIONAL
Study Start Date
2021-02-28
Study Completion Date
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have metabolic syndrome or type 2 diabetes, which have severe acute respiratory syndrome secondary to SARS-CoV-2.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
NCT04625985
Severe Acute Respiratory Syndrome Coronavirus 2
COMPLETED
PHASE2
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
NCT00871936
Type 2 Diabetes
COMPLETED
PHASE2
Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes
NCT01386671
Type 2 Diabetes
COMPLETED
PHASE3
Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers
NCT01560481
Healthy
COMPLETED
PHASE1
Efficacy Study of Metformin Glycinate on Postprandial Lipemia
NCT02064881
Type 2 Diabetes
UNKNOWN
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After being informed about the study and potential risks, all patients will give written informed consent and undergo a 1 day screening period to determine the eligibility for study entry. At day 0, patients who meet the eligibility requirements will be randomized in a double blind (participant and investigator) in a 1:1 ratio to metformin glycinate (620 mg, taken orally twice daily) plus standard treatment or placebo (taken orally,twice daily) plus standard treatment, both will be for 14 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Severe Acute Respiratory Syndrome Coronavirus 2
Metabolic Syndrome
Type 2 Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Experimental group: Metformin glycinate 620 mg bid (PO) plus standard treatment for 14 days. Control Group: Placebo bid (PO) plus standard treatment for 14 days plus
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Parallel assignment experimental and placebo tablets will have same physical appearance and medicine box will be identified by kit number
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin glycinate
620 mg bid (PO) plus standard treatment for 14 days
Group Type
EXPERIMENTAL
metformin glycinate
Intervention Type
DRUG
Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
Placebo
Placebo tablets bid (PO) plus standard treatment for 14 days
Group Type
PLACEBO_COMPARATOR
Placebo oral tablet
Intervention Type
DRUG
Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
metformin glycinate
Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
Intervention Type
DRUG
Placebo oral tablet
Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
DMMET
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. ≥ 18 years old
2. Ability to understand and the willingness to sign a written informed consent document before any study procedure
3. Metabolic syndrome or type 2 diabetes
4. Coronavirus infection, severe acute respiratory syndrome SARS-CoV- 2 confirmed by the Polymerase Chain Reaction test (PCR) ≤ 4 days before of the randomization.
5. Hospitalized patient.
6. Radiographic evidence of pulmonary infiltrates
2. Ability to understand and the willingness to sign a written informed consent document before any study procedure
3. Metabolic syndrome or type 2 diabetes
4. Coronavirus infection, severe acute respiratory syndrome SARS-CoV- 2 confirmed by the Polymerase Chain Reaction test (PCR) ≤ 4 days before of the randomization.
5. Hospitalized patient.
6. Radiographic evidence of pulmonary infiltrates
Exclusion Criteria
1. Participation in any other clinical trial of an experimental treatment for COVID-19
2. Evidence of multi-organ failure
3. Require mechanical ventilation before randomization
4. Pregnant patients
2. Evidence of multi-organ failure
3. Require mechanical ventilation before randomization
4. Pregnant patients
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Silanes S.A. de C.V.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fausto González-Villagrán, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Juárez de México, OPD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Juárez de México, OPD
Mexico City, , Mexico
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Mexico
References
Explore related publications, articles, or registry entries linked to this study.
Revert F, Ventura I, Martinez-Martinez P, Granero-Molto F, Revert-Ros F, Macias J, Saus J. Goodpasture antigen-binding protein is a soluble exportable protein that interacts with type IV collagen. Identification of novel membrane-bound isoforms. J Biol Chem. 2008 Oct 31;283(44):30246-55. doi: 10.1074/jbc.M805026200. Epub 2008 Sep 4.
Reference Type
BACKGROUND
Glucophage Product Monograph (metformin hydrochloride) Sanofi-Aventis Canada. Rev.28th October 2008
Reference Type
BACKGROUND
NDA 20-357, Glucophage. US Food and Drug Administration. Center for Drug Evaluation and Research. Freedom of Information Office. New Drug Approval Packages. Pharmacology/Toxicology Review.
Reference Type
BACKGROUND
NDA 21-842, Actoplus met. US Food and Drug Administration. Center for Drug Evaluation and Research. Freedom of Information Office. New Drug Approval Packages. Pharmacology/Toxicology Review.
Reference Type
BACKGROUND
Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem. 1988 Sep 15;263(26):13374-80.
Reference Type
RESULT
Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. 2003 Jun 19;348(25):2543-56. doi: 10.1056/NEJMra022296. No abstract available.
Reference Type
RESULT
Quinones S, Bernal D, Garcia-Sogo M, Elena SF, Saus J. Exon/intron structure of the human alpha 3(IV) gene encompassing the Goodpasture antigen (alpha 3(IV)NC1). Identification of a potentially antigenic region at the triple helix/NC1 domain junction. J Biol Chem. 1992 Oct 5;267(28):19780-4.
Reference Type
RESULT
Revert F, Penades JR, Plana M, Bernal D, Johansson C, Itarte E, Cervera J, Wieslander J, Quinones S, Saus J. Phosphorylation of the Goodpasture antigen by type A protein kinases. J Biol Chem. 1995 Jun 2;270(22):13254-61. doi: 10.1074/jbc.270.22.13254.
Reference Type
RESULT
Borza CM, Borza DB, Pedchenko V, Saleem MA, Mathieson PW, Sado Y, Hudson HM, Pozzi A, Saus J, Abrahamson DR, Zent R, Hudson BG. Human podocytes adhere to the KRGDS motif of the alpha3alpha4alpha5 collagen IV network. J Am Soc Nephrol. 2008 Apr;19(4):677-84. doi: 10.1681/ASN.2007070793. Epub 2008 Jan 30.
Reference Type
RESULT
Raya A, Revert-Ros F, Martinez-Martinez P, Navarro S, Rosello E, Vieites B, Granero F, Forteza J, Saus J. Goodpasture antigen-binding protein, the kinase that phosphorylates the goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis. J Biol Chem. 2000 Dec 22;275(51):40392-9. doi: 10.1074/jbc.M002769200.
Reference Type
RESULT
Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, Nishijima M. Molecular machinery for non-vesicular trafficking of ceramide. Nature. 2003 Dec 18;426(6968):803-9. doi: 10.1038/nature02188.
Reference Type
RESULT
Revert F, Merino R, Monteagudo C, Macias J, Peydro A, Alcacer J, Muniesa P, Marquina R, Blanco M, Iglesias M, Revert-Ros F, Merino J, Saus J. Increased Goodpasture antigen-binding protein expression induces type IV collagen disorganization and deposit of immunoglobulin A in glomerular basement membrane. Am J Pathol. 2007 Nov;171(5):1419-30. doi: 10.2353/ajpath.2007.070205. Epub 2007 Oct 4.
Reference Type
RESULT
Revert-Ros F, Lopez-Pascual E, Granero-Molto F, Macias J, Breyer R, Zent R, Hudson BG, Saadeddin A, Revert F, Blasco R, Navarro C, Burks D, Saus J. Goodpasture antigen-binding protein (GPBP) directs myofibril formation: identification of intracellular downstream effector 130-kDa GPBP-interacting protein (GIP130). J Biol Chem. 2011 Oct 7;286(40):35030-43. doi: 10.1074/jbc.M111.249458. Epub 2011 Aug 9.
Reference Type
RESULT
Darris C, Revert F, Revert-Ros F, Gozalbo-Rovira R, Feigley A, Fidler A, Lopez-Pascual E, Saus J, Hudson BG. Unicellular ancestry and mechanisms of diversification of Goodpasture antigen-binding protein. J Biol Chem. 2019 Jan 18;294(3):759-769. doi: 10.1074/jbc.RA118.006225. Epub 2018 Oct 30.
Reference Type
RESULT
Revert F, Revert-Ros F, Blasco R, Artigot A, Lopez-Pascual E, Gozalbo-Rovira R, Ventura I, Gutierrez-Carbonell E, Roda N, Ruiz-Sanchis D, Forteza J, Alcacer J, Perez-Sastre A, Diaz A, Perez-Paya E, Sanz-Cervera JF, Saus J. Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden. Oncotarget. 2018 Jan 19;9(13):11020-11045. doi: 10.18632/oncotarget.24280. eCollection 2018 Feb 16.
Reference Type
RESULT
Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, Brenton JD, Downward J, Nicke B. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 2007 Jun;11(6):498-512. doi: 10.1016/j.ccr.2007.04.011.
Reference Type
RESULT
Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006 Sep;7(9):880-5. doi: 10.1038/sj.embor.7400779.
Reference Type
RESULT
Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol. 2019 Sep 8;73:529-557. doi: 10.1146/annurev-micro-020518-115759. Epub 2019 Jun 21.
Reference Type
RESULT
Catanzaro N, Meng XJ. Induction of the unfolded protein response (UPR) suppresses porcine reproductive and respiratory syndrome virus (PRRSV) replication. Virus Res. 2020 Jan 15;276:197820. doi: 10.1016/j.virusres.2019.197820. Epub 2019 Nov 16.
Reference Type
RESULT
Schimmack G, Defronzo RA, Musi N. AMP-activated protein kinase: Role in metabolism and therapeutic implications. Diabetes Obes Metab. 2006 Nov;8(6):591-602. doi: 10.1111/j.1463-1326.2005.00561.x.
Reference Type
RESULT
Sriwijitkamol A, Musi N. Advances in the development of AMPK-activating compounds. Expert Opin Drug Discov. 2008 Oct;3(10):1167-76. doi: 10.1517/17460441.3.10.1167.
Reference Type
RESULT
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002 Jul;51(7):2074-81. doi: 10.2337/diabetes.51.7.2074.
Reference Type
RESULT
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005 Dec 9;310(5754):1642-6. doi: 10.1126/science.1120781. Epub 2005 Nov 24.
Reference Type
RESULT
Detaille D, Guigas B, Leverve X, Wiernsperger N, Devos P. Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function. Biochem Pharmacol. 2002 Apr 1;63(7):1259-72. doi: 10.1016/s0006-2952(02)00858-4.
Reference Type
RESULT
Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550-4. doi: 10.1056/NEJM199508313330903.
Reference Type
RESULT
Otto M, Breinholt J, Westergaard N. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab. 2003 May;5(3):189-94. doi: 10.1046/j.1463-1326.2003.00263.x.
Reference Type
RESULT
Fery F, Plat L, Balasse EO. Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism. 1997 Feb;46(2):227-33. doi: 10.1016/s0026-0495(97)90307-3.
Reference Type
RESULT
Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh). 1989 Mar;120(3):257-65. doi: 10.1530/acta.0.1200257.
Reference Type
RESULT
Tamura Y, Watada H, Sato F, Kumashiro N, Sakurai Y, Hirose T, Tanaka Y, Kawamori R. Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab. 2008 Sep;10(9):733-8. doi: 10.1111/j.1463-1326.2007.00801.x. Epub 2007 Oct 15.
Reference Type
RESULT
Fischer M, Timper K, Radimerski T, Dembinski K, Frey DM, Zulewski H, Keller U, Muller B, Christ-Crain M, Grisouard J. Metformin induces glucose uptake in human preadipocyte-derived adipocytes from various fat depots. Diabetes Obes Metab. 2010 Apr;12(4):356-9. doi: 10.1111/j.1463-1326.2009.01169.x.
Reference Type
RESULT
Cataldo NA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC, Reaven GM. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod. 2006 Jan;21(1):109-20. doi: 10.1093/humrep/dei289. Epub 2005 Sep 9.
Reference Type
RESULT
Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med. 2009 Jun;26(6):649-54. doi: 10.1111/j.1464-5491.2009.02748.x.
Reference Type
RESULT
Standeven KF, Ariens RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes. 2002 Jan;51(1):189-97. doi: 10.2337/diabetes.51.1.189.
Reference Type
RESULT
Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab. 2007 Jan;9(1):96-102. doi: 10.1111/j.1463-1326.2006.00580.x.
Reference Type
RESULT
Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010 Feb;33(2):322-6. doi: 10.2337/dc09-1380. Epub 2009 Nov 16.
Reference Type
RESULT
Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG, Barrera-Duran C, Gonzalez-Canudas J. Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012 Dec;14(12):1140-4. doi: 10.1089/dia.2012.0097. Epub 2012 Sep 13.
Reference Type
RESULT
JORGE GONZÁLEZ-CANUDAS, COMET GROUP Diabetes Efficacy and Safety of Metformin Glycinate vs. Metformin Hydrochloride in Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Mellitus Patients. Diabetes 2019 Jun; 68(Supplement 1):
Reference Type
RESULT
Garza-Ocañas L, Tamez-de la O E, Iglesias-Chiesa J, Gonzalez Canudas J, Rivas-Ruiz R: Pharmacokinetics and gastrointestinal tolerability of DMMET 01 (glycinate of metformin): results of a prospective randomized trial in healthy volunteers [abstract]. Diabetes 2009;58(Suppl 1):A533.
Reference Type
RESULT
Granero F, Revert F, Revert-Ros F, Lainez S, Martinez-Martinez P, Saus J. A human-specific TNF-responsive promoter for Goodpasture antigen-binding protein. FEBS J. 2005 Oct;272(20):5291-305. doi: 10.1111/j.1742-4658.2005.04925.x.
Reference Type
RESULT
Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010 Jul;120(7):2355-69. doi: 10.1172/JCI40671. Epub 2010 Jun 23.
Reference Type
RESULT
Rada P, Mosquera A, Muntane J, Ferrandiz F, Rodriguez-Manas L, de Pablo F, Gonzalez-Canudas J, Valverde AM. Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice. Food Chem Toxicol. 2019 Jan;123:470-480. doi: 10.1016/j.fct.2018.11.019. Epub 2018 Nov 9.
Reference Type
RESULT
Choi YH, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin. Br J Pharmacol. 2006 Oct;149(4):424-30. doi: 10.1038/sj.bjp.0706875. Epub 2006 Aug 29.
Reference Type
RESULT
Dianben® 1000 mg polvo para solución oral. Ficha técnica del producto. Nº de autorización de comercialización: 70545. Merck Santé S.A.S. 37 rue Saint Romain. 69008 Lyon. Francia. Fecha de revision 2010. Consultada en la web de la Agencia Española del Medicamento y de Productos Sanitarios (www.aemps.gob.es) el 27 de Marzo del 2013
Reference Type
RESULT
Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993 Oct;16(10):1387-90. doi: 10.2337/diacare.16.10.1387.
Reference Type
RESULT
Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991 Feb;229(2):181-7. doi: 10.1111/j.1365-2796.1991.tb00328.x.
Reference Type
RESULT
Quaile MP, Melich DH, Jordan HL, Nold JB, Chism JP, Polli JW, Smith GA, Rhodes MC. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol. 2010 Mar 15;243(3):340-7. doi: 10.1016/j.taap.2009.11.026. Epub 2010 Jan 13.
Reference Type
RESULT
Santure M, Pitre M, Gaudreault N, Marette A, Nadeau A, Bachelard H. Effect of metformin on the vascular and glucose metabolic actions of insulin in hypertensive rats. Am J Physiol Gastrointest Liver Physiol. 2000 May;278(5):G682-92. doi: 10.1152/ajpgi.2000.278.5.G682.
Reference Type
RESULT
Verma S, Bhanot S, McNeill JH. Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1334-7.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIL-30000-II(1)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
NCT04943692
SUSPENDED
PHASE3
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
NCT00698789
TERMINATED
PHASE2
Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
NCT01969318
COMPLETED
PHASE2
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
NCT00290940
COMPLETED
PHASE2
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
NCT01787396
COMPLETED
PHASE3
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
NCT01990469
COMPLETED
PHASE3
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
NCT02926950
COMPLETED
PHASE3
A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)
NCT00868790
TERMINATED
PHASE2
Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet
NCT00541437
COMPLETED
Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics
NCT00698230
COMPLETED
PHASE2
Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus
NCT00519142
COMPLETED
PHASE3
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
NCT01708902
COMPLETED
PHASE3
Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)
NCT00543751
TERMINATED
PHASE3
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
NCT04604678
WITHDRAWN
PHASE2
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
NCT01929863
COMPLETED
PHASE2
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
NCT01459809
COMPLETED
PHASE3
Safety Study of BMS-823778 in Subjects With Type 2 Diabetes
NCT01111955
COMPLETED
PHASE2
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
NCT01512979
COMPLETED
PHASE4
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
NCT01956929
COMPLETED
PHASE1
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
NCT01046422
COMPLETED
PHASE2
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
NCT00309608
COMPLETED
PHASE2
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
NCT00947557
TERMINATED
PHASE3
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
NCT02554877
COMPLETED
PHASE2
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes
NCT00672386
COMPLETED
PHASE2